 Home > Active Ingredient News > Drugs Articles > Oyster Point Pharma announced that it has reached an exclusive license agreement with Jixing Pharmaceutical to develop and commercialize two drugs for the treatment of dry eye in Greater China

Oyster Point Pharma announced that it has reached an exclusive license agreement with Jixing Pharmaceutical to develop and commercialize two drugs for the treatment of dry eye in Greater China

 Last Update: 2021-08-14
 Source: Internet
 Author: User

Tags

5 htp drugs class

dry black soybeans

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Jixing Pharmaceutical will develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for dry eye patients in Greater China

Oyster Point Pharma will receive a down payment of US$17.
5 million and up to 0.
75% of the shares of Jixing Pharmaceutical

Oyster Point Pharma is eligible to receive up to USD 204.
8 million in potential development and sales-based milestone payments, as well as a sales share based on future net sales

Princeton, New Jersey and Shanghai, China - Oyster Point Pharma (NASDAQ: OYST) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic drugs
.

The company recently announced that it has reached an exclusive license and cooperation agreement with Jixing Pharmaceutical ("Jixing") to develop and commercialize OC-01 (varenicline) and OC-01 (varenicline) and OC-02 (simpinicline) nasal spray

Princeton, New Jersey and Shanghai, China——

"Our goal is to benefit dry eye patients around the world from OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays.
This collaboration is an important step towards our goal and also strengthens our cash.
flow situation
.

"Oyster Point Pharma president and CEO Jeffrey Nau said," we look forward to working with Kei star team, the development of novel therapies in areas such licensed and commercializing where possible

"There are more than 150 million dry eye patients in China, and the treatment that stimulates natural tear film secretion may change the existing treatment model for dry eye
.

" said Mr.

According to the terms of the agreement, Oyster Point will grant Jixing an exclusive license to develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) for patients with eye diseases in Greater China
.

Oyster Point will receive a cash down payment of US$17.
5 million and up to 0.

About dry eye

Dry eye is a chronic and progressive disease, which affects more than 30 million people in the United States and affects more than 150 million people in China
.

It is estimated that 16 million adults in the United States have been diagnosed with dry eye, a disease of the ocular surface caused by a variety of factors, characterized by damage to the tear film

About OC-01 (varenicline) nasal spray

OC-01 (varenicline) nasal spray is a multi-dose packaged, preservative-free, highly selective cholinergic agonist nasal spray, used to treat the symptoms and signs of dry eye and neurotrophic keratopathy
.

The parasympathetic nervous system is mainly responsible for the "rest and digestion" system of the human body, and can partly control the tear film homeostasis through the trigeminal nerve in the nasal cavity

About OC-02 (simpinicline) nasal spray

OC-02 (simpinicline) nasal spray is a highly selective cholinergic agonist
.

Simpinicline citrate is a strong nicotinic acetylcholine receptor agonist, which is active on α4β2, α3β4, α3α5β4 and α4α6β2 receptors, and has weak agonistic activity on α7 receptors

About Jixing Pharmaceutical

Jixing Pharmaceutical is a privately held biopharmaceutical company headquartered in Shanghai
.

Jixing was invested and founded by RTW Investments, dedicated to serving Chinese patients suffering from serious life-threatening diseases, providing them with innovative scientific therapies and drugs to solve unmet clinical needs

About RTW Investments

RTW Investments (hereinafter referred to as "RTW") is a global life-cycle investment company headquartered in New York, focusing on discovering transformative and disruptive innovations in biopharmaceuticals and medical technology
.
As a leading partner in industry and academia, RTW combines deep scientific expertise with solution-oriented investment methods to help emerging medical therapies, companies and scholars who develop these therapies
.

For more information about RTW, please visit
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.